Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma

Inclusion Criteria

• •Disease Characteristics:
• •Patients with a documented histologic or cytologic diagnosis of B-cell NHL.
• •Age Range: Male or Female at least 18 years of age
• •Performance Status: Patients with a Karnofsky performance status \> 60% (or equivalent, ECOG 0-2) and expected survival of at least 12 weeks.
• •Hematopoietic: Hemoglobin \> 10 g/dL; ANC \> 1.5x10\^9/L; Platelets \> 100x10\^9/L;
• •Hepatic: Serum bilirubin \< 2.0 mg/dL; AST and ALT \< 2 x ULN w/o liver metastases or \<5 x ULN w/liver metastases
• •Renal: Creatinine \< 2.0 mg/dL
• •Cardiovascular: Patients with LVEF \>/= 50% by MUGA or 2D-ECHO.
• •Pulmonary: Patients with DFCO and FEV1 \>/= 60% by required Pulmonary Function Tests.
• •Other: Patients agreeing to use a medically effective method of contraception while enrolled in the study. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the study. Patients able to understand and give written informed consent.